Results

Total Results: over 10,000 records

Showing results for "described".

  1. effectivehealthcare.ahrq.gov/sites/default/files/pdf/erythropoiesis-stimulating-agents-utilization_research.pdf
    February 01, 2011 - agents among Medicare beneficiaries with kidney disease Erythropoietins Data Points #4 The findings described … The work described herein was commissioned for presentation at the March 24, 2010, Medicare Evidence … These groups are more thoroughly described in the subsequent Definitions and Methodology section. … 4 Relating Timing of Practice and Policy Events to Potential Impact on ESA Use As previously described … DEFINITIONS AND METHODOLOGY Eligible Population Unless otherwise specified, the ESA utilization described
  2. Psn-Pdf (pdf file)

    psnet.ahrq.gov/node/865813/psn-pdf
    May 08, 2024 - Participants reported increased convenience (e.g., patients not having to miss work), but also described
  3. Psn-Pdf (pdf file)

    psnet.ahrq.gov/node/866316/psn-pdf
    July 17, 2024 - In this study, recently hospitalized patients described the various ways they tried to improve their
  4. Psn-Pdf (pdf file)

    psnet.ahrq.gov/node/36889/psn-pdf
    May 28, 2024 - Research and Quality https://psnet.ahrq.gov/issue/surveys-patient-safety-culture Safety culture has been described
  5. Psn-Pdf (pdf file)

    psnet.ahrq.gov/node/867640/psn-pdf
    February 26, 2025 - Patients and providers described limitations with describing and examining relevant symptoms, as patients
  6. effectivehealthcare.ahrq.gov/sites/default/files/pdf/cancer-ovarian-contraceptives_research-protocol.pdf
    March 13, 2012 - This process is described further in section IV F. … The safety outcomes will be framed to help identify adverse events as described in KQ 5. … Data necessary for assessing quality and applicability, as described in the General Methods Guide,20 … These outcomes were de- prioritized following the ranking process described in Sections II and IV … These outcomes were de-prioritized following the ranking process described in Sections II and IV
  7. Psn-Pdf (pdf file)

    psnet.ahrq.gov/node/854636/psn-pdf
    October 18, 2023 - customization and individualization (e.g., simplifying medication regimens for certain patients) and described
  8. Psn-Pdf (pdf file)

    psnet.ahrq.gov/node/849330/psn-pdf
    May 24, 2023 - Prescribers described the usefulness of CDS but also noted alert fatigue.
  9. Psn-Pdf (pdf file)

    psnet.ahrq.gov/node/838019/psn-pdf
    September 07, 2022 - This study characterizes safety measures described in incident reports from German outpatient care settings
  10. Psn-Pdf (pdf file)

    psnet.ahrq.gov/node/851055/psn-pdf
    June 28, 2023 - In this study, surgical trainees described factors influencing their decisions not to disclose errors
  11. Psn-Pdf (pdf file)

    psnet.ahrq.gov/node/50887/psn-pdf
    February 12, 2020 - Successful elements are described, and the authors conclude that an openness to continuous improvement
  12. Psn-Pdf (pdf file)

    psnet.ahrq.gov/node/851648/psn-pdf
    July 26, 2023 - In this study, 25 hospitalized Black patients with serious illness described their experiences with
  13. Psn-Pdf (pdf file)

    psnet.ahrq.gov/node/841762/psn-pdf
    December 21, 2022 - In this study, nurse anesthetists and intensive care nurses described strategies to ensure safe transport
  14. Psn-Pdf (pdf file)

    psnet.ahrq.gov/node/47776/psn-pdf
    August 20, 2021 - A WebM&M commentary described the challenges and benefits associated with robotic surgery.
  15. Psn-Pdf (pdf file)

    psnet.ahrq.gov/node/73465/psn-pdf
    July 07, 2021 - Most errors described usability issues which should be considered and addressed to improve medication
  16. Psn-Pdf (pdf file)

    psnet.ahrq.gov/node/841474/psn-pdf
    January 01, 2023 - The challenges and strategies described in the publication can be used by health systems to accelerate
  17. Psn-Pdf (pdf file)

    psnet.ahrq.gov/node/48110/psn-pdf
    August 14, 2019 - A recent WebM&M commentary described how leaders can encourage and reward speaking up.
  18. Psn-Pdf (pdf file)

    psnet.ahrq.gov/node/39057/psn-pdf
    December 30, 2014 - a missing dose clarification request, a related near miss, and medication name confusion are also described
  19. Psn-Pdf (pdf file)

    psnet.ahrq.gov/node/35288/psn-pdf
    September 12, 2016 - A number of dramatic cases are described (including several that were fatal), as are some of the challenges
  20. psnet.ahrq.gov/web-mm/acute-care-admission-behavioral-health-patient
    July 19, 2023 - In addition, the GI consult described how the patient requested a reduction in the haloperidol dose because … Adverse motor effects associated with this antagonism (e.g., Parkinsonism and dystonia) were described … At least one case report has described this pattern with olanzapine.( 11 ) Withdrawal dyskinesias, presumably … related to dopaminergic sensitivity, are also described.( 12 ) Additional discontinuation symptoms,